Fossaluzza V, Di Benedetto P, Pinat F, Pasqualini M, Massarutto C, Pirrone S, Rossi P, Tosato F, Lucas C, Padovani R
Minerva Med. 1983 Mar 31;74(13):723-6.
A long term open study of the use of thiopronine in the treatment of 38 patients with ARA classified "classic" or "definite" rheumatoid arthritis is reported. Doses of the drug were increased from an initial 250 mg per diem by the addition of 250 mg every 15 days to 1 g per diem. After 6 months testing, results were satisfactory (good and fair) in 65% of the cases in both biological and clinical terms. In 15% of the cases, treatment was interrupted mainly due to mucous and cutaneous side effects. These preliminary results confirm reports in the literature and encourage further experiment.
本文报告了一项关于硫普罗宁治疗38例美国风湿病学会(ARA)分类为“典型”或“确诊”类风湿性关节炎患者的长期开放性研究。药物剂量从最初的每日250毫克开始,每15天增加250毫克,直至每日1克。经过6个月的试验,从生物学和临床角度来看,65%的病例结果令人满意(良好和尚可)。15%的病例治疗中断,主要是由于黏膜和皮肤副作用。这些初步结果证实了文献中的报道,并鼓励进一步实验。